When Verily unveiled $700 million in funding late last year, it said the cash would support its Covid-19 research. Some of those research plans are now taking shape. Verily, the life sciences division ...
Renal outcomes and chimeric antigen receptor (CAR) T-cell therapy efficacy were unaffected by baseline renal status in a cohort of patients with diffuse large B cell lymphoma, but acute kidney injury ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback